LEAD, Shanghai ChemPartner Ink Agreement

LEAD Therapeutics has entered a research collaboration with Shanghai ChemPartner, a subsidiary of ShangPharma.

ShangPharma is a Chinese pharmaceutical and biotechnology R&D outsourcing company. LEAD is a chemistry-driven drug discovery company based in San Francisco that plans to carry out the majority of its research in China.

Peter Myers, LEAD’s chairman and CEO, said the collaboration will accelerate the company’s efforts toward developing pre-investigational new drug candidates.